Key Takeaways
- Record FY25, driven by mix shift: Revenue hit ₹2,565 crore (+33% YoY) and PAT jumped 82% to ₹357 crore, as the Derivatives & Specialty revenue share moved from 45% to 54%.
- Chlorine integration is the structural story: Captive chlorine consumption reached 72%, with a path to 80-85% by FY27 as new derivative plants ramp, insulating Epigral from the weak global chlorine cycle that is depressing caustic soda ECU margins industry-wide.
- Q4 margin normalisation, not deterioration: EBITDA margin of 28% (vs 30% in Q4 FY24) was called "more realistic" by management, with the prior-year peak driven by unusually low raw material costs.
- Next leg of growth is funded and scoped: A ₹450 crore FY26 capex plan, a 100-acre land parcel for new chemistry, and capacity doublings in CPVC and Epichlorohydrin set a 15-20% volume CAGR ambition, though the ₹5,000 crore revenue vision was walked back as realisation-dependent.
- What to watch next quarter: The pace of chlorotoluene customer approvals and ramp-up, CPVC pricing trajectory amid a soft real estate cycle, and any Board decision on the new chemistry value chain.
Chlorine Integration & the ECU Hedge
- The core structural advantage: Epigral consumes 72% of its chlorine captively, and management expects this to reach 80-85% once the expanded CPVC (1,50,000 tonnes) and Epichlorohydrin (1,00,000 tonnes) capacities come on stream in FY27, with a long-term ambition of 100% integration.
- Why it matters now: Global caustic soda prices remain firm on strong alumina and nickel demand, but the chlorine leg of the ECU is depressed globally (60-65% downstream utilisation) and chlorine prices in India are at their lowest. By consuming chlorine internally, Epigral avoids selling into a weak merchant market and captures the derivative margin instead.
- Chlorine price outlook improving: Management sees the negative chlorine realisation (around -₹5,000 in Q4) improving as agrochemical demand revives and domestic chlorine derivative applications grow.
- Pipeline sales capped: External pipeline chlorine sales are capped at roughly 20% of output and will remain constant, meaning incremental chlorine will flow into higher-value internal derivatives.
- Caustic soda efficiency step-up: A major membrane and electrolyser replacement completed in May 2025 will improve operational efficiency from Q1 FY26 onwards.
Maulik Patel: "once it reached at optimum level, we are 90% going to be a internal and captive consumption going forward and the pipeline customers are hardly it is 20% maximum right now, and that is going to be remain constant."
Derivatives & Specialty: The Mix Shift in Motion
- Revenue contribution crossed the halfway mark: Derivatives & Specialty rose to 54% of FY25 revenue from 45% in FY24, driven by the chlorotoluene value chain commissioning and ramp-up of CPVC and Epichlorohydrin. Management targets ~70% once all three expansions reach optimal utilisation.
- Chlorotoluene: the near-term ramp-up story: The plant was commissioned in March 2025 and trial production is with customers for approval, a process expected to take six to eight months. Optimal utilisation is targeted by Q4 FY26, meaning FY25 contributes almost nothing and FY26 captures the ramp.
- CPVC: volume up, pricing soft: CPVC resin and compound plants are ramping in line with demand, but pricing faces headwinds because real estate sector growth is slower than last year and raw material PVC is at a cycle-low globally. Margins are expected to hold in-line as raw material costs have fallen alongside realisations.
- Epichlorohydrin: slightly firmer trend: ECH realisations are expected to be on a "slightly higher side" for the next couple of quarters, and the capacity doubling to 1,00,000 tonnes is targeted for H1 FY27.
- Hydrogen peroxide softness absorbed: Hydrogen peroxide realisations declined in Q4, but other derivative products compensated, keeping the overall EBITDA margin at 28%. Management did not provide a product-specific margin defence plan.
Growth Roadmap: Capacity, Capex & New Chemistry
- FY26 capex set at ~₹450 crore: Funding will come from internal accruals and debt if required; no QIP is planned. Management may take debt even if accruals are sufficient, to avoid disturbing project speed.
- Volume growth algorithm: 10-15% volume CAGR is targeted over the next five years, with 15-20% possible in the next four to five years assuming demand holds. FY26 volume growth will come primarily from the CPVC capacity added last year, ECH running at full swing, and caustic efficiency gains.
- New chemistry, new location: Epigral has acquired 100 acres of land one kilometre from its existing site and is evaluating a couple of new chemistry value chains based on India's 10-year growth story. Management explicitly ruled out entering similar chlor-alkali chemistry. The Board has not yet approved any plan, and no capex figure has been decided.
- Debottlenecking on the horizon: Minor debottlenecking of the chlor-alkali plant is being considered once chlorine integration reaches 90%, but it is too early to quantify the capex.
- ₹5,000 crore revenue vision walked back: Management said the figure was based on peak realisations from two years ago and declined to commit to a specific number in a specific year, though internal targets exist.
Maulik Patel: "We are not going to enter in the similar chlor-alkali that... we are looking for a couple of chemistry which we are planning to do it based on the India growth story on the next 10 years."
Margins: Normalisation, Not Erosion
- Q4 EBITDA margin of 28% framed as realistic: The 30% margin in Q4 FY24 was driven by raw material prices that were already low relative to realisations. Management called 28% a "good number" and more representative of the business's earning power.
- Long-term margin guidance sustained at 25%: Management reiterated that 25% EBITDA margin is achievable on a longer-term basis, supported by the business model and improving revenue mix toward derivatives.
- Power cost headwind in Q4: Power costs rose both YoY and QoQ because solar and wind generation was lower due to a natural phenomenon, and coal costs increased slightly versus the prior year.
- Product-wise margins undisclosed: Management declined to share the highest-margin product, its percentage of sales, or market share data, citing competitive sensitivity.
Milind Kotecha: "Even at 28% is something which is, is good number. And considering the guidance that we had given, it was around 25%. So it's not a drop of by 2% in fact, 28% itself is more like a realistic number rather than 30%."
Market Context: Caustic Firm, Chlorine Weak
- Global caustic soda demand robust: Alumina and nickel mining consumption keeps caustic soda demand strong, and management expects caustic prices to remain firm through FY26 and beyond.
- Chlorine chemistry the global bottleneck: Downstream chlorine utilisation is only 60-65% globally, with the PVC cycle at its lowest level, keeping chlorine prices depressed worldwide. This structural imbalance is what Epigral's captive chlorine strategy is designed to bypass.
- Indian chlorine pricing at a floor: Chlorine prices in India are at their lowest relative to international levels, and management expects them to move forward as domestic derivative demand grows.
- Scale barrier rising in chlor-alkali: Management noted that smaller greenfield chlor-alkali plants will not be feasible going forward; the economy of scale has moved up, and new large-capacity players will push volume into global markets, adjusting to global prices.
Maulik Patel: "caustic soda price are remaining soft globally, the reason behind is the downstream chemistry which is used chlorine globally, which is almost 60% to 65% that is very low... we are thinking that the caustic soda will remain firm even current this financial year, as well as going forward also."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Chlorotoluene ramp-up | Reach optimal utilisation | By Q4 FY26 (Dec/Jan timeframe) |
| Derivatives & Specialty revenue share | Reach ~70% of total revenue | Once chlorotoluene, CPVC resin, and ECH expansions reach optimal utilisation |
| Captive chlorine consumption | Reach 80-85% | By FY27, when ECH and CPVC expanded capacities come on stream |
| Epichlorohydrin capacity expansion | Double to 1,00,000 tonnes | First half of FY27 |
| CPVC resin capacity expansion | Double to 1,50,000 tonnes | Timeline not specified; announced in Q4 FY25 |
| FY26 capex | ~₹450 crore | FY26 |
| Volume growth | 10-15% CAGR | Next five years |
| Long-term EBITDA margin | 25% achievable | Longer-term basis |
| Caustic soda efficiency improvement | Benefit from membrane and electrolyser replacement | From Q1 FY26 onwards |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue | ₹631 crore, +20% YoY vs ₹526 crore in Q4 FY24 |
| EBITDA | ₹173 crore, +12% YoY vs ₹155 crore in Q4 FY24 |
| PAT | ₹87 crore, +13% YoY vs ₹77 crore in Q4 FY24; margin at 14% |
| FY25 revenue | ₹2,565 crore, highest ever, +33% vs FY24 |
| FY25 PAT | ₹357 crore, highest ever, +82% vs ₹196 crore in FY24 |
| FY25 EBITDA | ₹711 crore, +48% YoY; EBITDA margin 28% vs 25% in FY24 |
| FY25 capacity utilization | 81% vs 78% in FY24 |
| FY25 ROCE | 25% including CWIP vs 17% in FY24; 28% excluding CWIP |
| Net debt-to-EBITDA | 0.7x at end March 2025 vs 2.0x at end March 2024 |
| Derivatives & Specialty revenue contribution | 54% in FY25 vs 45% in FY24 |
| Captive chlorine consumption | 72% in FY25 |
| ECU realization | ~₹33,000, chlorine at ~negative ₹5,000 |
| FY26 CAPEX plan | ~₹450 crore |
| FY26 volume growth guidance | 10% to 15% driven by CPVC, ECH ramp-up and chlorotoluene contribution |
| CRISIL rating | Upgraded to CRISIL AA Stable from CRISIL AA- positive outlook |